Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cell Source's share price for the quarter that ended in Sep. 2023 was $0.6. Cell Source's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 38.50 Mil. Therefore, Cell Source's market cap for the quarter that ended in Sep. 2023 was $23.10 Mil.
Cell Source's quarterly market cap
declined
from Mar. 2023 ($15.61 Mil) to Jun. 2023 ($0.03 Mil) but then
increased
from Jun. 2023 ($0.03 Mil) to Sep. 2023 ($23.10 Mil).
Cell Source's annual market cap
declined
from Dec. 2020 ($65.08 Mil) to Dec. 2021 ($44.00 Mil) and
declined
from Dec. 2021 ($44.00 Mil) to Dec. 2022 ($30.67 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cell Source's Enterprise Value for Today is $9.50 Mil.
Cell Source Market Cap Historical Data
The historical data trend for Cell Source's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cell Source's Market Cap
For the Biotechnology subindustry, Cell Source's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Source's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cell Source's Market Cap distribution charts can be found below:
* The bar in red indicates where Cell Source's Market Cap falls into.
Cell Source Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cell Source's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cell Source (OTCPK:CLCS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cell Source Market Cap Related Terms
Thank you for viewing the detailed overview of Cell Source's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLCS has been successfully added to your 